RADX

Radiopharm Theranostics Ltd RADX

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $3.6M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$2.77M

Quarter to Jun 30

Net income

$-56.95M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.31M total
Stonepine Capital Management, LLC
$794.0K+100.0%
HSBC HOLDINGS PLC
$253.7K+1.3%
Regal Partners Ltd
$168.2K0.0%
PNC FINANCIAL SERVICES GROUP, INC.
$83.8K+25.0%
UBS Group AG
$6.3K-49.8%
Integrated Wealth Concepts LLC
$5.5KNew
RHUMBLINE ADVISERS
$817+61.2%
See all 7 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2026
EDGAR

Net Income

FY 2026
EDGAR

EPS (Diluted)

FY 2026
EDGAR

Loading ratio trend…

RADX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Radiopharm Theranostics Ltd's annual filings on SEC EDGAR.

Radiopharm Theranostics Ltd reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2026$2.8M$-57.0M—
FY 2025$3.6M$-38.3M—
FY 2024$299.2K$-47.9M—
FY 2023$292.4K$-34.6M—
Source: RADX filings on SEC EDGAR →

About Radiopharm Theranostics Ltd (RADX): stock profile, AI score and financials

Radiopharm Theranostics Ltd (RADX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. RADX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $3.6m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2026), Radiopharm Theranostics Ltd reports quarterly revenue of $2.8M, net income of $-57.0M. Top institutional holders of RADX by reported 13-F value include Stonepine Capital Management, HSBC PLC, Regal Partners Ltd, based on the most recent SEC filings. RADX trades on the Nasdaq exchange and files with the SEC under CIK 1949257. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RADX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Radiopharm Theranostics Ltd directly from SEC EDGAR.

SEC EDGAR: CIK 1949257 →